Drug resistance of cancer cells // Drug Repurposing

Drug resistance of cancer cells

Pao and his colleagues have identified some common mechanisms of acquired resistance to targeted therapies, including the development of second mutations in the driver oncogenes that alter drug binding. However, the full spectrum of DNA changes associated with this resistance is unknown.

Now, Pao and colleagues including Zhongming Zhao, Ph.D., associate professor of Biomedical Informatics, and Peilin Jia, Ph.D., research assistant professor of Biomedical Informatics, have combined next-generation sequencing technologies and bioinformatics analyses to screen for genome-wide genetic mutations associated with drug resistance in a series of lung cancer cell lines.

“The recent advances in next-generation sequencing offer us the opportunity to explore the full range of DNA changes acquired in the course of cancer cell drug resistance, ” Jia said.

The investigators focused on lung cancer cell lines that harbor mutations in the EGFR (epidermal growth factor receptor) gene.

They developed genetically matched pairs of drug-sensitive and drug-resistant cell lines by culturing the “parental” drug-sensitive cells in escalating doses of EGFR-targeted inhibitors, such as erlotinib (Tarceva), until the cells developed resistance to the drug.

Using next-generation sequencing technologies, they sequenced the whole genome or whole exome (the “expressed” part of the genome) and compared mutational changes in resistant lines and their parental counterparts. They found that resistant cells acquired between 18 and 91 new single nucleotide variations, insertions and deletions, and lost between one and 27 mutations.

The researchers were surprised to find more copy number variations (CNVs) — a type of mutation where large repeated regions of DNA are inserted or deleted — across all resistant cell lines.

“We found a large burden of CNV changes across all resistant cell lines, ” Zhao said. “Among these changes, a surprising finding was that one of the cell lines displaying an EMT (epithelial mesenchymal transition) phenotype had far more CNV alterations than the others. This study in general reflects the strong mutational heterogeneity of cancer.”

The results, Pao said, provide a framework for studying how drug-related genetic variations evolve over time. In future studies, the investigators will use this framework to examine the effects of different types and doses of targeted therapies on the evolution of drug resistance, and they will extend their analyses of resistance mechanisms to non-targeted chemotherapies and radiation.

Pao is the Cornelius Abernathy Craig Professor and leads Vanderbilt-Ingram’s Personalized Cancer Medicine initiative, an effort to routinely determine the genetic changes that drive tumors and select treatments that target those changes. Zhao is an Ingram Associate Professor of Cancer Research and Chief Bioinformatics Officer of Vanderbilt-Ingram.

You might also like

Targeting Drug-Resistant Cancer (Brainstorm Ep124)
Targeting Drug-Resistant Cancer (Brainstorm Ep124)
Powerful Form of Ecstasy Drug Kills Blood Cancer Cells - 8
Powerful Form of Ecstasy Drug Kills Blood Cancer Cells - 8 ...

New accidental cancer cell killing compound

by ------fyi------


WASHINGTON (Reuters) [edited for 2400 char]
Schaefer and colleagues at the University of Rochester Medical Center in New York believe they have discovered a new way to attack tumors that have learned how to evade existing drugs.
Tests in mice suggest the compound helps break down the cell walls of tumors, almost like destroying a tumor cell's "skeleton."
She was testing a compound called a PPAR-gamma modulator [peroxisome proliferator-activated receptor-gamma modulator]. It would never normally have been thought of as a cancer drug, or in fact a drug of any kind

The point is that

by coelentrate

I haven't seen any evidence that taxol treatment gives you a taxol resistant tumour. The idea makes sense, but it's not observed in cancer patients.
Sure, Mrp2 conveys drug resistance, but there's no evidence that a chemotherapy drug selects for cells with high Mrp2 activity. One red mark against this being the case is that this would be slightly inconsistent with the idea of cancer stem cells.

Springer Drug Resistance in Cancer Cells
Book (Springer)

Awards presented at Hoyle School  — spectator.southcoasttoday
He noted that Lt. Cabral served as the Drug Awareness Resistance Education (DARE) officer for three years without being paid after the town went through a difficult financial time.

Humana Press Cancer Drug Resistance (Cancer Drug Discovery and Development)
Book (Humana Press)
HETEROGENEITY OF CANCER CELL POPULATION WITH REGARD TO THE NATURAL DRUG RESISTANCE OF CANCER CELL
Book (PN)
The Mechanism and New Approach on Drug Resistance of Cancer Cells: Proceedings of the International Symposium on the Mechanism and New Approach on D (International Congress Series)
Book (Excerpta Medica)
Academic Press Mechanisms of Drug Resistance in Neoplastic Cells: Bristol-Myers Cancer Symposia, Volume 9
Book (Academic Press)